Compounders Research Compare

Definium Therapeutics, Inc.(DFTX)

Biotechnology · New York, NY

$35.70-0.53 (-1.48%)

Delayed quote: Oct 6, 2026, 11:35 AM EDT

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

New York, NY

106 employees

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Robert Barrow

View full financials

Earnings Yield: N/A

Basis: Unrounded diluted TTM EPS / FMP quote price × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The earnings yield is N/A as of 2026-10-06T15:36:21.733Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:36:21.733Z.

Quote observation: 2026-10-06T15:35:12.000Z. Amounts in USD. The price header may show a later quote.

Unrounded diluted TTM EPS · period ending 2026-06-30: -3.43
Quote price: 35.695

FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d

P/E Ratio|FCF Yield|Dividend Yield|All Metrics

DFTX Earnings Yield Metrics

EARNINGS YIELD

N/A

DFTX Competitors' Earnings Yield

Definium Therapeutics, Inc.

Current

Market Cap

$4.74B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LifeStance Health Group, Inc.

Market Cap

$4.69B

Earnings Yield

1.07%

TTM Avg

0.64%

3Y Avg

0.64%

5Y Avg

0.64%

Option Care Health, Inc.

Market Cap

$4.64B

Earnings Yield

4.29%

TTM Avg

4.92%

3Y Avg

4.57%

5Y Avg

3.88%

BillionToOne, Inc.

Market Cap

$4.62B

Earnings Yield

0.62%

TTM Avg

0.37%

3Y Avg

0.37%

5Y Avg

0.37%

Oruka Therapeutics, Inc.

Market Cap

$4.88B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Dianthus Therapeutics, Inc.

Market Cap

$4.91B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Mirum Pharmaceuticals, Inc.

Market Cap

$4.93B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Indivior Pharmaceuticals Inc

Market Cap

$4.44B

Earnings Yield

7.83%

TTM Avg

5.11%

3Y Avg

3.07%

5Y Avg

3.43%

Adaptive Biotechnologies Corporation

Market Cap

$4.42B

Earnings Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Merit Medical Systems, Inc.

Market Cap

$5.08B

Earnings Yield

2.84%

TTM Avg

2.80%

3Y Avg

2.38%

5Y Avg

2.05%

NAME	MARKET CAP	EARNINGS YIELD	TTM	3Y	5Y
Definium Therapeutics, Inc. (DFTX)	$4.74B	N/A	N/A	N/A	N/A
LifeStance Health Group, Inc. (LFST)vs ›	$4.69B	1.07%	0.64%	0.64%	0.64%
Option Care Health, Inc. (OPCH)vs ›	$4.64B	4.29%	4.92%	4.57%	3.88%
BillionToOne, Inc. (BLLN)vs ›	$4.62B	0.62%	0.37%	0.37%	0.37%
Oruka Therapeutics, Inc. (ORKA)vs ›	$4.88B	N/A	N/A	N/A	N/A
Dianthus Therapeutics, Inc. (DNTH)vs ›	$4.91B	N/A	N/A	N/A	N/A
Mirum Pharmaceuticals, Inc. (MIRM)vs ›	$4.93B	N/A	N/A	N/A	N/A
Indivior Pharmaceuticals Inc (INDV)vs ›	$4.44B	7.83%	5.11%	3.07%	3.43%
Adaptive Biotechnologies Corporation (ADPT)vs ›	$4.42B	N/A	N/A	N/A	N/A
Merit Medical Systems, Inc. (MMSI)vs ›	$5.08B	2.84%	2.80%	2.38%	2.05%

Earnings Yield vs P/E Ratio

Earnings Yield

N/A

EPS ÷ Price

P/E Ratio

N/A

Price ÷ EPS

Formula: Earnings Yield = (EPS / Price) × 100

Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.

How earnings yield is used:

It expresses earnings relative to share price as a percentage
It can be compared with FCF yield and dividend yield
It can be compared with bond yields because both are percentages
It is mathematically the inverse of the P/E ratio

Earnings Yield Formula & Definition

Earnings Yield = EPS (TTM) / Share Price

Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

P/E Ratio FCF Yield Dividend Yield All Metrics